Full Press Release Details
Inc. Appoints Jeffrey M. Busch as Interim Chief Executive Officer; Founder and Former CEO of $1B NYSE Enterprise Which Delivered
~8.5% Dividends to Shareholders
Seasoned executive who founded and built a NYSE-listed healthcare
real estate company to over $1 billion in enterprise value - delivering an average dividend yield of approximately 8.5% to shareholders
- brings capital markets depth, healthcare sector expertise, and commercial discipline to lead Aditxt's next chapter of revenue-driven
Mountain View, California - June 1, 2026
- Aditxt, Inc. (Nasdaq: ADTX)("Aditxt" or the "Company"), a life sciences platform company
accelerating promising health innovations, today announced the appointment of Jeffrey M. Busch as Interim Chief Executive Officer of
Aditxt, Inc., effective May 31, 2026. Mr. Busch, who has served as Chief Executive Officer of Aditxt's CLIA-certified
precision oncology diagnostics subsidiary Ignite Proteomics, LLC ("Ignite") since March 2026, will now lead the full
Aditxt enterprise as it executes an accelerated commercialization strategy centered on Ignite's precision oncology diagnostics
platform. Mr. Busch simultaneously continues in his role as CEO of Ignite.
The Board of Directors expressed its deep appreciation
for the contributions of outgoing CEO Amro Albanna, who resigned as CEO, from the Company's Board and from all positions with the
Company's subsidiaries. Mr. Albanna co-founded Aditxt and led the Company through its founding vision, public listing, and acquisition
strategy, including the addition of Ignite to the Aditxt portfolio. Mr. Albanna's scientific conviction and entrepreneurial persistence
established the foundation upon which the Company's next chapter will be built. The Board wishes him well in his future endeavors.
brings exactly the combination of skills this moment requires: public company leadership, capital markets credibility, deep healthcare-sector
expertise, and a track record of building shareholder value in a regulated, mission-driven environment. We are confident that under his
leadership, Aditxt will accelerate the commercial trajectory of Ignite Proteomics while ensuring that every decision reflects our responsibility
to patients, partners, employees, and investors alike."
- Brian Brady, Chairman of the Board, Aditxt,
About Jeffrey M. Busch
Mr. Busch is the Founder, Chairman, and former
Chief Executive Officer of Global Medical REIT, Inc. (NYSE: GMRE), now Chiron Real Estate, Inc. (NYSE: XRN), a NYSE-listed net-lease healthcare
real estate investment trust that he founded and built to over $1 billion in enterprise value. Throughout his tenure as CEO, Mr. Busch
maintained a consistent and disciplined dividend program, delivering an average annual dividend yield of approximately 8.5% to common
shareholders - a track record that reflects both his commitment to capital stewardship and his ability to build institutional-grade
infrastructure within a regulated, healthcare-focused business environment.
A graduate of the New York University Stern School
of Business with a Bachelor of Science in Business, Mr. Busch also holds a Master of Public Administration specializing in health policy
from New York University and a Juris Doctor from Emory University. His academic foundation spans law, business, and health policy -
a rare combination that has informed both his regulatory approach and his commercial strategy throughout a career at the intersection
of healthcare and capital markets.
Earlier in his career, Mr. Busch served as a congressional
aide before being appointed by two United States Presidents to serve in their administrations, including as a United States Delegate to
the United Nations in Geneva. Since 2001, he has served as President of the Safe Blood International Foundation, overseeing the establishment
of medical facilities in 35 developing nations - programs funded by the CDC, USAID, ExxonMobil, and the Gates Foundation. This global
health mission underscores a career defined not only by financial performance, but by a genuine commitment to expanding access to life-saving
"Aditxt and Ignite sit at
one of the most important intersections in modern medicine - precision diagnostics and patient-centered oncology care. With approximately
40% of cancer drugs not working for the patients they are prescribed to, the clinical imperative behind what Ignite does could not be
more clear. My focus will be on translating that clinical imperative into a commercially excellent, financially disciplined, and patient-first
organization. We have a Medicare-reimbursed platform, growing clinical validation, established research partnerships, and a large and
expanding addressable market. The work ahead is to build on that foundation with urgency and accountability - to our patients, to
our people, and to our shareholders."
- Jeffrey M. Busch, Interim Chief
Executive Officer, Aditxt, Inc.
Strategic Priorities Under New
Under Mr. Busch's leadership, Aditxt intends to
advance the following core strategic priorities:
Aditxt, Inc. (Nasdaq: ADTX) is a life sciences
platform company focused on accelerating promising health innovations. Through its subsidiary Ignite Proteomics, Aditxt operates a CLIA-certified
precision oncology diagnostics laboratory that uses Reverse Phase Protein Array (RPPA) technology to help physicians identify the most
effective cancer treatment for each individual patient. Ignite holds a Medicare PLA code and has established clinical collaborations with
leading cancer research institutions including Dana-Farber Cancer Institute and Vanderbilt University Medical Center.
About Ignite Proteomics
Ignite Proteomics is a CLIA-certified precision
oncology diagnostics company utilizing proprietary Reverse Phase Protein Array (RPPA) technology to deliver functional protein-level analysis
that guides cancer treatment selection. With Medicare reimbursement established through a dedicated PLA code and growing clinical validation
across multiple cancer types, Ignite is positioned to address one of oncology's most persistent challenges: ensuring that the right patient
receives the right therapy at the right time.
Important Note Regarding Historical Dividend References
References in this press release to dividend yield, dividend history,
enterprise value, capital stewardship, shareholder value creation, or other historical performance metrics relate solely to Mr. Busch's
prior service at Global Medical REIT, Inc., now Chiron Real Estate, Inc., and are provided only as biographical background regarding Mr.
Busch's prior professional experience. Such references do not relate to Aditxt, Inc. and should not be understood as a statement,
projection, forecast, commitment, or indication that Aditxt intends to declare, pay, initiate, maintain, or recommend dividends or any
other distributions to stockholders.
Aditxt does not currently have a dividend policy and has no current
plan or intention to declare or pay cash dividends or other distributions to stockholders. Any future determination regarding dividends,
if ever considered, would be subject to the discretion and approval of Aditxt's Board of Directors and would depend on, among other
things, Aditxt's financial condition, operating results, capital requirements, liquidity, contractual restrictions, applicable law,
and other factors the Board may deem relevant. Investors should not infer from Mr. Busch's prior experience at another public company
that Aditxt will adopt any similar dividend, capital allocation, financing, investor relations, or shareholder return strategy.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws.
Forward-looking statements include all statements other than statements of historical fact, including, without limitation,
statements regarding Aditxt, Inc.'s expectations, plans, objectives, strategy, priorities, business outlook, leadership
transition, anticipated benefits of the appointment of Jeffrey M. Busch as Interim Chief Executive Officer, the expected impact of
Mr. Busch's prior public company, healthcare, capital markets, operational, commercial, and strategic experience,
Aditxt's ability to advance, commercialize, grow, finance, scale, or otherwise realize value from Ignite Proteomics or any of
Aditxt's other businesses, assets, subsidiaries, platforms, technologies, products, services, intellectual property,
collaborations, clinical initiatives, regulatory strategies, reimbursement opportunities, market opportunities, investor relations
initiatives, capital markets activities, strategic partnerships, or other corporate objectives.
Forward-looking statements may include words such as "anticipate,"
"believe," "continue," "could," "estimate," "expect," "intend,"
"may," "plan," "potential," "pursue," "seek," "should," "target,"
"will," "would," "accelerate," "advance," "build," "commercialize,"
"expand," "enhance," "execute," "grow," "improve," "lead," "support,"
"transform," and similar words, phrases, or expressions, although not all forward-looking statements contain these identifying
These forward-looking statements include, but
are not limited to, statements regarding Aditxt's expectations concerning its new leadership structure; the Company's
ability to transition successfully following the appointment of a new Interim Chief Executive Officer; the ability of the new
Interim Chief Executive Officer to implement any strategic, operational, commercial, financing, investor relations, capital
allocation, or other initiatives; the Company's ability to execute an accelerated commercialization strategy centered on
Ignite Proteomics; the potential clinical utility, commercial opportunity, market demand, reimbursement potential, revenue
potential, scalability, validation, adoption, or competitive position of Ignite's precision oncology diagnostics platform,
including its Reverse Phase Protein Array technology; the Company's ability to maintain, utilize, expand, or benefit from CLIA